Dr. Necchi on Impact of PD-1 Inhibition in Bladder Cancer

Andrea Necchi, MD
Published Online: Friday, Nov 17, 2017



Andrea Necchi, MD, a medical oncologist at the Fondazione IRCCS Istituto Nazionale dei Tumori in Milan, discusses the impact of PD-1 inhibition in bladder cancer as well as the promise with combination strategies.

It is known that treatment with pembrolizumab (Keytruda) alone, as well as other single-agent checkpoint inhibitors, will not significantly improve progression-free survival in patients with bladder cancer, explains Necchi. 

There are multiple international, phase I, II, and III combination trials being conducted in the field of bladder cancer, Necchi adds. These are combining immune checkpoint inhibitors with other checkpoint inhibitors, PD-1 agents combined with antiangiogenesis therapy, or checkpoint inhibitors combined with more personalized therapeutic approaches. These studies could provide many new possibilities for patients, and is an advantage and a positive next step for the field, he concludes. 

<<< View more from the 2017 EMUC Congress


Andrea Necchi, MD, a medical oncologist at the Fondazione IRCCS Istituto Nazionale dei Tumori in Milan, discusses the impact of PD-1 inhibition in bladder cancer as well as the promise with combination strategies.

It is known that treatment with pembrolizumab (Keytruda) alone, as well as other single-agent checkpoint inhibitors, will not significantly improve progression-free survival in patients with bladder cancer, explains Necchi. 

There are multiple international, phase I, II, and III combination trials being conducted in the field of bladder cancer, Necchi adds. These are combining immune checkpoint inhibitors with other checkpoint inhibitors, PD-1 agents combined with antiangiogenesis therapy, or checkpoint inhibitors combined with more personalized therapeutic approaches. These studies could provide many new possibilities for patients, and is an advantage and a positive next step for the field, he concludes. 

<<< View more from the 2017 EMUC Congress

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Clinical Interchange™: Translating Research to Inform Changing Paradigms: Assessment of Emerging Immuno-Oncology Strategies and Combinations across Lung, Head and Neck, and Bladder CancersOct 31, 20182.0
Publication Bottom Border
Border Publication
x